Physician profile
Mitchell Weiser
NPI 1417920836
$4,616.88
in general payments reported to CMS, 2019-2025
27 companies · $175 in 2025
The $175 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,187 · 2020: $605 · 2021: $696 · 2022: $1,055 · 2023: $252 · 2024: $649 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,010 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,009.76 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $444.61 | 2020-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $426.68 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $417.89 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $388.80 | 2019-2024 | Atacand |
| Pfizer INC. | $333.26 | 2019-2024 | |
| Boston Scientific Corporation | $320.13 | 2019-2024 | Watchman Flx, Watchman Access System |
| Sanofi-Aventis U.S. LLC | $318.81 | 2019-2023 | |
| Amgen INC. | $264.17 | 2019-2024 | Repatha |
| Arbor Pharmaceuticals, INC. | $230.02 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $210.79 | 2019-2025 | Camzyos, Eliquis |
| Kowa Pharmaceuticals America, INC. | $201.65 | 2019-2023 | Livalo |
| Abbott Laboratories | $196.26 | 2022-2024 | Cardiomems |
| Novo Nordisk INC | $190.85 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Regeneron Healthcare Solutions, INC. | $161.73 | 2019-2022 | |
| Amarin Pharma, INC. | $131.53 | 2019-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $99.25 | 2022-2024 | Verquvo |
| Cvrx, INC. | $97.48 | 2022-2024 | Barostim Neo System |
| Esperion Therapeutics, INC. | $43.52 | 2020-2021 | |
| Kiniksa Pharmaceuticals, LTD. | $27.47 | 2022 | |
| Preventice Services, LLC | $19.98 | 2019 | |
| Azurity Pharmaceuticals, INC. | $14.54 | 2022 | |
| Gilead Sciences, INC. | $13.69 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $13.25 | 2024 | Arcalyst |
| Heartflow, INC. | $13.18 | 2023 | Ffrct |
| Portola Pharmaceuticals, LLC | $13.17 | 2019 | |
| Alnylam Pharmaceuticals INC. | $12.85 | 2022 | |
| Irhythm Technologies, INC. | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Weiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.